|
|
|
UPCC 24309
|
Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas |
II |
Proton Therapy |
Not Applicable |
|
UPCC 23811
|
A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma |
II |
Signal Transduction Inhibitor |
dovitinib |
|
CDX110-06
|
A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma |
II |
Immunotherapy, Signal Transduction Inhibitor |
bevacizumab; sargramostim; rindopepimut; KLH Pulsed Dendritic Cell Vaccine |
|
UPCC 08309
|
Proton Radiation for Low Grade Gliomas |
I / II |
Proton Therapy |
Not Applicable |
|
CDR0000579896
|
Phase I/II Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma |
I / II |
Chemotherapy |
temozolomide; iniparib |
|
ABTC-1101
|
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment |
I |
Chemotherapy, Other |
temozolomide |
|
UPCC 08310
|
Detection of Vascular and Neuronal Changes Following Proton and/or Photon Radiotherapy in Patients Receiving Skull Base and/or Brain Radiation |
Not Specified |
Proton Therapy |
Not Applicable |